Questions discussed in this category
Risk factors include: non-IgG subtype, abnormal serum light chain ratio, M-protein >=1.5 mg/dL.
Further work up could include imaging, bone marrow...
AL amyloid biopsy proven on renal biopsy. Normal SPEP and FLC, bone marrow biopsy with 10-15% plasma cells.
Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.
Are there specific guidelines for managing this patient population?
Since free light chains are removed by dialysis and SPEP can also be impacted, is there a reliable way to monitor patients with ESRD and MM?
If there are light chain deposits on the kidney, is that conclusive of MGRS?
11419232211833021041206382077618089132366518
Papers discussed in this category
The New England journal of medicine, 2024 Dec 09
European journal of haematology, 2013 Aug 17
European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes, 2021 Dec 06
Kidney international, 2018-07
BMC nephrology, 2019-02-14
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2019 Oct 09
N Engl J Med,